Study of HCB101 combined with other drugs for advanced stomach or gastro-esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new combination treatment for advanced stomach or gastro-esophageal cancer that has not responded to standard treatments. The trial aims to see if the drug combination is safe and effective, potentially offering a new option for people with this type of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have advanced stomach or gastro-esophageal cancer that is HER2-negative and CLDN18.2-positive (a specific protein marker).
- You must have at least one measurable tumor that can be evaluated.
- You must not have had prior systemic cancer therapy (including immunotherapy) for this cancer.
- You must have adequate organ function and be in generally good health (ECOG performance status 0–1).
- You must not have active brain metastases, uncontrolled heart problems, or certain infections like HIV, hepatitis B/C, or tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (zolbetuximab, pembrolizumab, and chemotherapy) for people with advanced stomach or gastroesophageal junction cancer. It may be an option if your tumor has certain proteins (CLDN18.2 and PD-L1) and you haven't had chemotherapy for advanced disease.
This study tests a new drug called zolbetuximab added to standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer. It may help slow the cancer's growth.
This trial tests new combinations of drugs alongside standard chemotherapy for people with advanced stomach or esophagus cancer that has not been treated yet. It aims to see if these combinations can shrink tumors or slow down the cancer better than current options.
This study looks at how well zolbetuximab works when combined with chemotherapy in people with advanced stomach or gastroesophageal junction cancer. It aims to help doctors understand the best ways to use this treatment in everyday practice.
This trial tests a new drug, HEC-921, given alone or with other cancer treatments for people with advanced solid tumors. It may be an option for those who have tried standard treatments or who have a specific marker on their tumor.
This trial tests a new immunotherapy drug called cadonilimab combined with chemotherapy for people with advanced stomach cancer that hasn't been treated yet. It compares this combination to chemotherapy with or without another immunotherapy drug, nivolumab.
Hear when a new GC/GEJC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.